Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are quite possibly the most maturely produced TPD approaches. During this review, we target both equally preclinical experiments and scientific trials to deliver a comprehensive summary of the security and clinical usefulness of PROTACs and MGDs in hematologic malignancies